> Danish drugmaker H. Lundbeck has tapped Sean Nolan as CEO of its U.S. business, Lundbeck Inc., succeeding Jeffrey Aronin.
> The board of directors of BELLUS Health has announced that Roberto Bellini has been named company president and CEO. As previously announced, Francesco Bellini is stepping down as president and CEO effective Dec. 31. Additionally, Charles Cavell has agreed to assume the responsibility of deputy chairman.
> Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, have announced BiPar President and CEO Hoyoung Huh will become chairman of the board of directors of BiPar, as well as chair of the newly formed BiPar innovation board. Additionally Atul Dhir has been appointed new BiPar CEO.
> Columbia Laboratories has announced the appointment of Frank Condella, Jr. as interim CEO. Robert Mills will continue to serve on the management team as president and COO.
> Sartorius's supervisory board has extended appointment of the group's CEO Joachim Kreuzburg to 2015.
> VaxInnate Corporation has named Thomas Hofstaetter, who led corporate business development at Wyeth, as its COO.
> Vertex Pharmaceuticals has tapped Nancy Wysenski to be its executive VP and chief commercial officer.
> AlphaRx has named Ruby Hui as president of China operations.
> Bristol-Myers Squibb has appointed Charles Bancroft as acting CFO after announcing that Jean-Marc Huet, executive VP and CFO, will leave the company at the end of 2009.
> NormOxys has appointed David Clark as its first chief medical officer. Clark will manage NormOxys' clinical affairs, including the development of its lead product candidate, OXY111A, which is expected to enter clinical trials in the first quarter of 2010.
> Oncolytics Biotech has announced the appointment of Alan Warrander to the role of senior VP, global licensing and business development.
> Concert Pharmaceuticals has appointed Lijun Wu as VP, Biology. In this newly created position, Wu will have responsibility for Concert's non-clinical pharmacology, pharmacokinetics, drug metabolism and bioanalytical functions.
> Access Pharmaceuticals has named Frank Jacobucci to the position of VP of sales and marketing. Jacobucci will be primarily responsible for the company's marketing launch of MuGard.
> Baxter International's board of directors of has elected two new corporate officers of the company. Mary Kay Ladone, VP of investor relations, has been appointed to serve as an officer of the company, and Stephanie Shinn, currently associate general counsel for Baxter, has also been named corporate secretary and appointed to serve as an officer of the company.
> Biogen has announced that William Young will become chairman of the company's board of directors, following the decision of the current chair, Bruce Ross, to step down.
> InVivo Therapeutics Corporation has added George Nolen, former president and CEO of Siemens Corporation, to its board of directors.
> Nektar Therapeutics has announced that Dennis Winger has been appointed to serve on its board of directors.
> Oxygen Biotherapeutics has expanded its board of directors by adding Lt. Gen. Ronald R. Blanck, DO, U.S. Army (Ret.).
> ImmunoCellular Therapeutics has appointed Colonel George Peoples, Constantine Ioannides and Cohava Gelber to its scientific advisory board.
> Mirna Therapeutics has announced the appointment of Chris Earl, Corey Goodman and Evan Melrose as outside directors to its board.
> GVK Biosciences has named Cecil Pickett as scientific advisor to the board of directors.